NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression
KRQE,
NRX-101 is first oral antidepressant to show 33% advantage in sustained remission in suicidality (not statistically significant…